Tianjin Lisheng Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of pharmaceutical products in China and internationally. T...
Tianjin Development Flags Sharp Profit Drop at Lisheng Pharmaceutical for H1 2026
Tianjin Development affiliate Lisheng Pharmaceutical invests RMB 180 million in Industrial Bank wealth products
UBS lowers the target price for SINO BIOPHARM to 11 yuan, rating it as "Buy"
Buying Platforms, Selling Pipelines: Deconstructing the Innovation Logic of SINO BIOPHARM
Tianjin Development's subsidiary Lishengpharma A's annual net profit increased by 125.6% to 416 million RMB, with a dividend of 60 cents RMB
Tianjin Development’s Pharma Unit Lisheng Posts Profit Surge and Proposes Dividend